Here's a link:
clinicaltrials.gov
I'm thinking that top line results can come after the preliminary completion date which is November 2018, though I'm uncertain of that. I've loaded up with January 14 calls, I believe they'll be well in the black by that time, but they are cheap now. Lots of other positive results will hopefully come from the technical conferences by the end of the year. If I'm right, I'll add shares that cost me very little, if I'm wrong it's cost me less than purchasing a couple hundred share.
I don't know that it could happen, but other investors were talking about an approval from the combination trials possibly before the Phase 3, it's a stretch, but if the FDA's getting more involved and seeing something good, anything is possible.
Personally I'm on a generic of Gleevec, but when it first was approved, it was approved very early in Phase 3 as the FDA saw it was getting great results. I called it a miracle drug for the drugmaker at that time, as remissions were complete as long as the drug continued to be taken. Now after stem cells my Dr. still wants me on it as the evidence still says it's the safest way to go. It's not that most don't stay in remission without it, but a smaller percentage come out of remission while staying on it. I know some experimentation is being done with breaks of a month, I've never done that, but my Dr. has permitted me to be off for up to a week on special occasions.
An early approval based on results would be awesome, but I'm not counting on that. Even if top line results aren't revealed by January, I believe that anticipation of results should buoy the stock to new 52 week highs.
Gary |
